RNAi药物-话题@MedSci

#RNAi药物#

13篇内容 | 912人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2149433, encodeId=673821494333d, content=<a href='/topic/show?id=1c1710265113' target=_blank style='color:#2F92EE;'>#高血压#</a><a href='/topic/show?id=0b2115543c9' target=_blank style='color:#2F92EE;'>#RNAi药物#</a> <a href='/topic/show?id=ac0e10646366' target=_blank style='color:#2F92EE;'>#Zilebesiran#</a>，注射一次可维持长达6个月的长期降压效果，并且这种新方法是安全的。一旦上市可能引爆市场，虽然价格贵，但是如果使用人群巨大，可以摊薄成本, objectTitle=NEJM：重磅！一针维持半年血压，长效降压药临床数据公布, objectType=article, longId=783066, objectId=36c4e83066a5, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/prescription-form-with-medical-stethoscope-9ZRKVHM.jpg, objectUrl=/article/show_article.do?id=36c4e83066a5, replyNumber=0, likeNumber=63, createdTime=2023-07-23, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=加利福尼亚, moduleDTOList=[ModuleDTO(moduleId=36c4e83066a5, moduleTitle=NEJM：重磅！一针维持半年血压，长效降压药临床数据公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36c4e83066a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2093040, encodeId=78e320930403e, content=<a href='/topic/show?id=0b2115543c9' target=_blank style='color:#2F92EE;'>#RNAi药物#</a><a href='/topic/show?id=be56234245' target=_blank style='color:#2F92EE;'>#Alnylam#</a> <a href='/topic/show?id=e33910494e3c' target=_blank style='color:#2F92EE;'>#lumasiran#</a>治疗<a href='/topic/show?id=a9df1049489d' target=_blank style='color:#2F92EE;'>#原发性高草酸尿症1型#</a>, objectTitle=FDA批准lumasiran治疗原发性高草酸尿症1型，Alnylam的RNAi帝国再下一城！, objectType=article, longId=742814, objectId=e662e42814a9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20221009/b9af039519294fe2903286c1e746ebea.jpg, objectUrl=/article/show_article.do?id=e662e42814a9, replyNumber=0, likeNumber=73, createdTime=2022-10-11, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e662e42814a9, moduleTitle=FDA批准lumasiran治疗原发性高草酸尿症1型，Alnylam的RNAi帝国再下一城！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e662e42814a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642616, encodeId=c644164261671, content=<a href='/topic/show?id=0b2115543c9' target=_blank style='color:#2F92EE;'>#RNAi药物#</a>, objectTitle=RNAi药物治疗乙肝的新药RG6346，疗效强且持久超过1年, objectType=article, longId=203508, objectId=85e2203508d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85e2203508d6, replyNumber=0, likeNumber=61, createdTime=2021-06-12, rootId=0, userName=ms9203727104890838, userId=a79422981940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85e2203508d6, moduleTitle=RNAi药物治疗乙肝的新药RG6346，疗效强且持久超过1年, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85e2203508d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642617, encodeId=b3ee164261e3e, content=<a href='/topic/show?id=0b2115543c9' target=_blank style='color:#2F92EE;'>#RNAi药物#</a>, objectTitle=全球第三款RNAi药物出炉，百亿美金市场谁主沉浮？, objectType=article, longId=204189, objectId=8eea2041892b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8eea2041892b, replyNumber=0, likeNumber=51, createdTime=2021-11-05, rootId=0, userName=ms9203727104890838, userId=a79422981940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8eea2041892b, moduleTitle=全球第三款RNAi药物出炉，百亿美金市场谁主沉浮？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8eea2041892b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642615, encodeId=308016426155f, content=<a href='/topic/show?id=0b2115543c9' target=_blank style='color:#2F92EE;'>#RNAi药物#</a>, objectTitle=RNAi药物STP705治疗原位皮肤鳞状细胞癌， II期临床试验中期分析获得阳性结果, objectType=article, longId=192022, objectId=d2621920220a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2621920220a, replyNumber=0, likeNumber=40, createdTime=2021-01-20, rootId=0, userName=ms9203727104890838, userId=a79422981940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2621920220a, moduleTitle=RNAi药物STP705治疗原位皮肤鳞状细胞癌， II期临床试验中期分析获得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2621920220a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642614, encodeId=b180164261484, content=<a href='/topic/show?id=0b2115543c9' target=_blank style='color:#2F92EE;'>#RNAi药物#</a>, objectTitle=Alynlam的RNAi药物lumasiran治疗原发性高草酸尿症，完成向欧盟和美国的申请, objectType=article, longId=191814, objectId=bcab1918142e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bcab1918142e, replyNumber=0, likeNumber=46, createdTime=2020-09-02, rootId=0, userName=ms9203727104890838, userId=a79422981940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bcab1918142e, moduleTitle=Alynlam的RNAi药物lumasiran治疗原发性高草酸尿症，完成向欧盟和美国的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bcab1918142e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642613, encodeId=2b91164261356, content=<a href='/topic/show?id=0b2115543c9' target=_blank style='color:#2F92EE;'>#RNAi药物#</a>, objectTitle=Alnylam的第二款RNAi药物Givlaari，获得欧盟批准治疗肝卟啉症, objectType=article, longId=189441, objectId=02d9189441ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02d9189441ee, replyNumber=0, likeNumber=45, createdTime=2020-09-22, rootId=0, userName=ms9203727104890838, userId=a79422981940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02d9189441ee, moduleTitle=Alnylam的第二款RNAi药物Givlaari，获得欧盟批准治疗肝卟啉症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02d9189441ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642612, encodeId=5c37164261245, content=<a href='/topic/show?id=0b2115543c9' target=_blank style='color:#2F92EE;'>#RNAi药物#</a>, objectTitle=2019年AsiaTIDES：Sirnaomics将展示RNAi药物STP705在肝癌动物模型中的数据 , objectType=article, longId=161220, objectId=bd21161220d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd21161220d3, replyNumber=0, likeNumber=47, createdTime=2019-08-20, rootId=0, userName=ms9203727104890838, userId=a79422981940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd21161220d3, moduleTitle=2019年AsiaTIDES：Sirnaomics将展示RNAi药物STP705在肝癌动物模型中的数据 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd21161220d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642611, encodeId=a965164261159, content=<a href='/topic/show?id=0b2115543c9' target=_blank style='color:#2F92EE;'>#RNAi药物#</a>, objectTitle=FDA批准**RNAi药物Onpattro用于治疗hATTR, objectType=article, longId=146513, objectId=4cca146513d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cca146513d5, replyNumber=0, likeNumber=46, createdTime=2018-10-24, rootId=0, userName=ms9203727104890838, userId=a79422981940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cca146513d5, moduleTitle=FDA批准**RNAi药物Onpattro用于治疗hATTR, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cca146513d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642610, encodeId=fa55164261051, content=<a href='/topic/show?id=0b2115543c9' target=_blank style='color:#2F92EE;'>#RNAi药物#</a>, objectTitle=**RNAi药物patisiran有望近期上市, objectType=article, longId=113627, objectId=9c3d11362efe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c3d11362efe, replyNumber=0, likeNumber=37, createdTime=2018-08-16, rootId=0, userName=ms9203727104890838, userId=a79422981940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c3d11362efe, moduleTitle=**RNAi药物patisiran有望近期上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c3d11362efe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642608, encodeId=6cce1642608c2, content=<a href='/topic/show?id=0b2115543c9' target=_blank style='color:#2F92EE;'>#RNAi药物#</a>, objectTitle=Arrowhead治疗乙肝RNAi药物临床研究取得进展, objectType=article, longId=39270, objectId=40c8392e019, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40c8392e019, replyNumber=0, likeNumber=45, createdTime=2014-11-09, rootId=0, userName=ms9203727104890838, userId=a79422981940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40c8392e019, moduleTitle=Arrowhead治疗乙肝RNAi药物临床研究取得进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40c8392e019)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642609, encodeId=2fcf164260996, content=<a href='/topic/show?id=0b2115543c9' target=_blank style='color:#2F92EE;'>#RNAi药物#</a>, objectTitle=Arrowhead公布RNAi药物ARC-520治疗乙肝临床二期研究数据, objectType=article, longId=42892, objectId=f8054289293, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8054289293, replyNumber=0, likeNumber=51, createdTime=2015-09-12, rootId=0, userName=ms9203727104890838, userId=a79422981940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8054289293, moduleTitle=Arrowhead公布RNAi药物ARC-520治疗乙肝临床二期研究数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8054289293)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642607, encodeId=d937164260e73, content=<a href='/topic/show?id=0b2115543c9' target=_blank style='color:#2F92EE;'>#RNAi药物#</a>, objectTitle=FDA授予Alnylam RNAi药物ALN-AT3孤儿药地位, objectType=article, longId=23241, objectId=b5832324158, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5832324158, replyNumber=0, likeNumber=52, createdTime=2014-02-18, rootId=0, userName=ms9203727104890838, userId=a79422981940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5832324158, moduleTitle=FDA授予Alnylam RNAi药物ALN-AT3孤儿药地位, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5832324158)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

2020-05-29

病毒猎手 (审核中...)

前往app查看评论内容

#高血压##RNAi药物# #Zilebesiran#，注射一次可维持长达6个月的长期降压效果，并且这种新方法是安全的。一旦上市可能引爆市场，虽然价格贵，但是如果使用人群巨大，可以摊薄成本

NEJM：重磅！一针维持半年血压，长效降压药临床数据公布

2023-07-23发表于加利福尼亚

lifestar (审核中...)

前往app查看评论内容

#RNAi药物##Alnylam# #lumasiran#治疗#原发性高草酸尿症1型#

FDA批准lumasiran治疗原发性高草酸尿症1型，Alnylam的RNAi帝国再下一城！

2022-10-11

ms9203727104890838 (审核中...)

前往app查看评论内容

#RNAi药物#

RNAi药物治疗乙肝的新药RG6346，疗效强且持久超过1年

2021-06-12

ms9203727104890838 (审核中...)

前往app查看评论内容

#RNAi药物#

全球第三款RNAi药物出炉，百亿美金市场谁主沉浮？

2021-11-05

ms9203727104890838 (审核中...)

前往app查看评论内容

#RNAi药物#

RNAi药物STP705治疗原位皮肤鳞状细胞癌， II期临床试验中期分析获得阳性结果

2021-01-20

ms9203727104890838 (审核中...)

前往app查看评论内容

#RNAi药物#

Alynlam的RNAi药物lumasiran治疗原发性高草酸尿症，完成向欧盟和美国的申请

2020-09-02

ms9203727104890838 (审核中...)

前往app查看评论内容

#RNAi药物#

Alnylam的第二款RNAi药物Givlaari，获得欧盟批准治疗肝卟啉症

2020-09-22

ms9203727104890838 (审核中...)

前往app查看评论内容

#RNAi药物#

2019年AsiaTIDES：Sirnaomics将展示RNAi药物STP705在肝癌动物模型中的数据 

2019-08-20

ms9203727104890838 (审核中...)

前往app查看评论内容

#RNAi药物#

FDA批准**RNAi药物Onpattro用于治疗hATTR

2018-10-24

ms9203727104890838 (审核中...)

前往app查看评论内容

#RNAi药物#

**RNAi药物patisiran有望近期上市

2018-08-16

ms9203727104890838 (审核中...)

前往app查看评论内容

#RNAi药物#

Arrowhead治疗乙肝RNAi药物临床研究取得进展

2014-11-09

ms9203727104890838 (审核中...)

前往app查看评论内容

#RNAi药物#

Arrowhead公布RNAi药物ARC-520治疗乙肝临床二期研究数据

2015-09-12

ms9203727104890838 (审核中...)

前往app查看评论内容

#RNAi药物#

FDA授予Alnylam RNAi药物ALN-AT3孤儿药地位

2014-02-18

科室
- - 订阅+
  - 更多科室
工具
服务